W ith the emergence of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus, the treatment of complicated joint infections, osteomyelitis, skin infections and nosocomial pneumonias has become increasingly problematic. [1] [2] [3] Linezolid (Zyvox, Pfizer, New York, New York, USA) was introduced in 2000 as the first member of the new oxazolidine synthetic group of antibiotics to help treat patients with these drugresistant pathogens. Linezolid acts through inhibiting protein synthesis by binding specifically to the bacterial 50S ribosomal subunit, thereby inhibiting the formation of a viable initiation complex. 4 5 Linezolid is usually well -tolerated, with few described adverse effects. 6 However, the safety of linezolid treatment has been established for use only up to 28 days. 6 7 Optic and peripheral neuropathies have been reported in patients with prolonged use outside the 28-day window. Investigators have postulated mitochondrial dysfunction as a possible aetiology, but the exact mechanism leading to linezolid-induced mitochondrial optic neuropathy is still unknown. [8] [9] [10] [11] [12] [13] [14] [15] [16] Here, we report a case of reversible bilateral optic neuropathies in a 6-year-old boy undergoing treatment with linezolid for MRSA osteomyelitis of the jaw, review the findings in the literature and propose a potential mitochondrial mechanism for linezolid-induced optic neuropathy (LION).
CASE REPORT
A 6-year-old Vietnamese boy presented with a 2-month history of painless, decreased vision in both eyes. Medical history included long-standing MRSA osteomyelitis of the right mandible. Current drugs included oral metronidazole (125 mg daily) and linezolid (170 mg twice daily); he was allergic to penicillin and vancomycin. Linezolid treatment had been going on for 1 year. Best-corrected visual acuity (BCVA) values were 20/400 in both eyes. Ishihara colour plates showed decreased colour vision in both eyes (2 of 15 plates OU). Brightness sense was subjectively diminished in both eyes. Pupils were round and reactive with no relative afferent pupillary defect. The anterior segment examination was unremarkable. Examination of the optic discs was remarkable for moderate bilateral, symmetrical optic disc hyperaemia, optic disc swelling, peripapillary retinal nerve fibre layer (PRNFL) swelling and vessel tortuosity ( fig 1A) . Dilated fundus examination was otherwise unremarkable. Fluorescein angiography did not show any optic disc leakage. The patient was unable to perform a reliable Humphrey visual field examination. Neurological examination was unremarkable.
Results of the initial laboratory tests were normal, including serum folate, thiamine, serum lead, computed tomography of the head and lumbar puncture with normal opening pressures. The patient was then diagnosed with bilateral optic neuropathies induced by long-term linezolid treatment. Linezolid treatment was discontinued TEMP  SUP NAS  INF TEMP   300   200   100   0  0  100  200  300  400  500   TEMP SUP  NAS  INF TEMP   109  71  73  122  227  261   151  198  252  192   140   245   S  N  T  I   229   163   84  203   154  82  135  258  175  156   105  139  208  230   219   200   S  T  N  I   213   217   124  133   300   200   100   0  0  100  200  300  400  500   TEMP  SUP NAS  INF TEMP   85  42  69  155  127  106   72   98  132  155   150   121   S  T  N  I   136   144   65  92   300   200   100   0  0  100  200  300  400  500   TEMP  SUP NAS  INF TEMP   38  65  106  154  175  65   57   130  159  89   188   79   S  N  T  I   109   173   70 84 1C) . Three months after discontinuation of treatment, BCVA improved slightly to 20/20 in both eyes, with stable colour vision shown by Ishihara colour plates (9 of 15 OU). Examination of the optic discs was remarkable for markedly decreased optic disc hyperaemia, the absence of optic disc swelling, decreased PRNFL swelling and an absence of vessel tortuosity in both eyes ( fig 1D) . Dilated fundus examination was otherwise unremarkable. PRNFL scan by OCT was carried out and showed a marked decrease in the 360˚average measurement (109.30 mm OD, 108.87 mm OS). Marked decreases in thickness were detected in the temporal (65 mm OD and 64 mm OS), superior (136 mm OD and 109 mm OS), inferior (144 mm OD) and nasal (92 mm OD) quadrants. Other quadrants remained stable ( fig 1E) . At the time of submission of this report, the patient had been stable for .9 months.
DISCUSSION
Linezolid represents the first member of the synthetic oxazolidinone group of antimicrobials designed to treat MRSA and vancomycin-resistant Enterococcus, and is well tolerated when used for ,28 days. [4] [5] [6] [7] The safety of linezolid has not been established beyond 28 days, and all reported cases of optic and peripheral neuropathies have occurred with use outside of the 28-day window. [8] [9] [10] [11] [12] [13] [14] [15] [16] Recent studies have also shown that linezolid has excellent posterior segment penetration, reaching inhibitory concentrations above the minimum inhibitory concentrations for most Gram-positive pathogens within 4 h after a single oral dose (600 mg) in both aqueous and vitreous samples. 5 Reports of at least 12 patients with LION have been published; the presenting symptoms, duration, treatment and results have varied (table 1) . [8] [9] [10] [11] [12] [13] [14] [15] In previously reported cases, the duration of treatment varied from 5 to 44 months at doses of 600 mg once or twice per day. Typical clinical findings at the time of diagnosis include bilateral decreases in visual acuities, BCVA ranging from 20/60 to counting fingers, caecocentral and arcuate visual field defects, and temporal pallor of the optic discs. [8] [9] [10] [11] [12] [13] [14] [15] Only two previous articles reported optic disc oedema or temporal PRNFL defects. 12 15 Some reports did not describe any objective findings from the clinical examination. 8 10 None of the previous reports described PRNFL swellings and only one showed a PRNFL OCT. [8] [9] [10] [11] [12] [13] [14] [15] Characteristic features of all the reported patients include the long-term use of linezolid and some visual recovery after discontinuation of the antibiotic. Among the 13 patients (including the current report), the median duration of linezolid treatment was 280 days (range 120-1505 days), well outside the 28-day safety window recommended by the manufacturer. Interestingly, 8 of 13 (62%) patients had osteomyelitis or infected prosthetic hardware that required chronic antibiotic treatment. These infections are often challenging, as they are indolent, involve bacteria that are drug resistant and require long-term antibiotic use. Termination of linezolid treatment resulted in dramatic and rapid improvement in visual status in all of the patients. It is interesting that 3 of the 12 patients received a steroid pulse treatment that either had no effect or worsened the visual field or visual acuity and delayed the visual recovery in two patients. [8] [9] [10] [11] [12] [13] [14] [15] [16] All cells depend on mitochondria for oxidative metabolism. However, the optic nerve may be particularly sensitive to mitochondrial dysfunction, as evidenced by a wide category of optic neuropathies of both genetic and acquired origin, which share common clinical features and produce mitochondrial impairment. [17] [18] [19] Retinal ganglion cells (RGCs) contribute axons, which travel together in the retinal nerve fibre layer towards the optic nerve. These axons are rich in mitochondria, especially in the unmyelinated intraocular and prelaminar region (and in the postlaminar region at the nodes of Ranvier); these have been interpreted as sites with high energy demands. 20 These axons are myelinated by oligodendroglia posterior to the lamina cribrosa, and thereby enjoy the efficiency of salutatory conduction. 21 To maintain their transparency, the prelaminar axons of the RGCs are unmyelinated and hence have slower conduction velocities when compared with the postlaminar myelinated portion of the same axons. 18 However, it is the ubiquitous presence of sodium and potassium channels that gives the unmyelinated portion the considerably greater energy required to maintain the electrical potential at resting states. 22 These observations are supported by electron microscopy studies showing an inverse relationship between the presence of mitochondria and myelination, and immunohistochemical studies indicating decreased cytochrome c oxidase staining, a marker of oxidative phosphorylation, posterior to the lamina cribrosa when compared with prelaminar RGC axons. [23] [24] [25] Therefore, RGCs with their long unmyelinated but active axons have a spatial dependence on mitochondria.
The papillomacular bundle (PMB) is composed mostly of parvocellular neurones, with few magnocellular neurones, both with considerably smaller-calibre RGCs. 26 The smaller size of these PMB axons (down to 0.6 mm in diameter) represents a physical limit to the axoplasmic transport of mitochondria, which average 0.5 mm in diameter. However, in so far as the mitochondria are created and replicated only in the soma, the RGCs must transport and distribute these mitochondria in an energy-dependent fashion along the optic nerve, all the way to the synaptic terminals, doing so within the short lifetime of the mitochondria (7-10 days). 18 27 Linezolid is designed to inhibit protein synthesis by binding specifically to 23S rRNA of the 50S ribosomal subunit and inhibiting the formation of a viable initiation complex, thereby inhibiting bacterial protein synthesis. 4 Mammalian ribosomes lack the 50S component, and hence linezolid produces little effect on normal mammalian protein synthesis. Unfortunately, mitochondria in mammalian cells remain vulnerable as they contain DNA and use ribosomes that more closely approximate that of bacteria. [17] [18] [19] Long-term lineozilid use has shown to interfere with bacterial ribosomes and possibly also with mitochondrial ribosomes, disrupting protein synthesis in mitochondria. This process can theoretically mimic the respiratory chain dysfunction seen in the mitochondrial optic neuropathies and produce an optic neuropathy similar, for example, to that seen in patients with Leber's hereditary optic neuropathy (LHON). Ophthalmoscopical features of the acute phase of LHON include teleangiectatic microangiopathy, vessel tortuosity and PRNFL swelling, particularly involving the PMB. In addition, the optic disc appears hyperaemic and swollen, but no leakage is noted in fluorescein angiography. Mitochondria, through their respiratory chain, are the major source of cellular reactive oxygen species (ROS) as a byproduct of ATP synthesis. The disruption of oxidative phosphorylation at any step in the respiratory chain leads to considerable energy depletion coupled with the accumulation of ROS in the RGCs. This accumulation of ROS lowers the electrical potential across the mitochondrial membrane and this opens the mitochondrial permeability transition pores, which acts as an apoptotic switch by releasing factors promoting cell death such as cytochrome c. 29 30 This mitochondrial dysfunction may also trigger compensating increases in mitochondria, manifesting on OCT as retinal nerve fibre oedema. 31 Previous reports showed a lack of response to corticosteroids in patients with optic neuropathy secondary to linezolid and further showed that steroid pulses worsened the visual field or visual acuity in two reported patients. [10] [11] [12] Linezolid creates noticeable RGC intraxonal swelling, which would not be responsive to corticosteroids. 32 In addition, corticosteroids can exacerbate mitochondrial dysfunction, thereby uncoupling oxidative phosphorylation, lowering ATP phosphorylation and aggravating energy deficits. 33 Recently, De Vriese et al 15 reported a patient with LION in whom they analysed the patient's muscle, kidney and liver samples for potential mitochondrial abnormalities. No major histological changes were found, but a marked decrease in the activity of complexes I and IV was noted in each tissue type by spectrophotometric assays. Similar results were also observed in experimental rats treated with linezolid for at least 2 weeks, with decreased protein levels of multiple complexes observed relative to control samples. 15 Although these results are preliminary, they support the hypothesis that mitochondrial function is compromised with long-term linezolid treatment.
The patient in our study has clinical findings that included marked optic disc swelling and notable PRNFL swelling. This case is the first to quantify PRNFL layer swelling as a result of linezolid-induced mitochondrial optic neuropathy, and to show resolution of the swelling after cessation of linezolid treatment. Consistent with previous reports, our patient showed toxicity only after long-term treatment. [8] [9] [10] [11] [12] [13] [14] [15] [16] Few patients develop this optic neuropathy from linezolid use as a consequence of this unusual long-term treatment, possibly reflecting a yet undetermined genetic susceptibility.
The clinical presentation of LION is similar to that seen in toxic, metabolic, and Cuban epidemic, pharmaceutical neuropathy and LHON. 17-19 26-28 This is not surprising as in all of these conditions, including long-term linezolid use, mitochondria are compromised. It is important for ophthalmologists to evaluate and follow-up patients taking long-term linezolid treatment (outside the 28-day US Food and Drug Administrationrecommended period), especially those with visual complaints. Once promptly recognised, immediate cessation of treatment may enable full visual recovery. A prospective, longitudinal study including patients already taking long-term linezolid is warranted to fully evaluate the clinical characteristics of LION, and to apply psychophysical and imaging measures for the early detection, characterisation and monitoring of subclinical evidence of optic nerve dysfunction. million people are infected with trachoma. Five million people are infected with its late stages and two million are blind because of it.
The trachoma biovar of C trachomatis can be subdivided into 15 serovars which are designated by the letters A-K based on the polymorphism in the sequence of the major outer membrane protein. 2 3 Serovasrs A-C can usually be isolated from patients with clinical trachoma in regions where trachoma is endemic.
Oculogenital infection caused by serovars D-K is common in developed countries and leads to inclusion conjunctivitis, also called paratrachoma. Up to 90% have concurrent urogenital infections.
Although the different groups of serovars display unique tissue tropisms, they are not tissue selective, and serovars D-F, J and K have all been isolated from conjunctival swabs taken from individuals with typical clinical signs of active trachoma. [4] [5] [6] [7] However, all these reports are from areas where trachoma is endemic.
Therefore, the traditional distinction between ocular and genital strains may have to be reconsidered.
Clinically, it is difficult to diagnose the beginning of trachoma or inclusion body conjunctivitis, and it is only by laboratory testing that the diagnosis can be confirmed. Among the available assays, nucleic acid amplification tests have proven superior in detecting, quantifying and genotyping C. trachomatis. 8 Because chlamydia is an intracellular organism, the correct swab technique is very important to obtain a positive test result. This includes firm rubbing with the swab in the fornix, which is unpleasant for the patient. Because chlamydial infection is freguently oligosymptomatic and routine laboratory screening is seldom not readily available for the ophthalmologist practitioner, the diagnosis of the disease is often delayed or even missed. Additionally, repeated reinfection occurs when the sexual partner is not treated as well.
These difficulties lead to a prolonged course of the infection and possibly to scarring due to chronic inflammation and repeated reinfections. Unfortunately, we were not able to differentiate the serovar of the C trachomatis isolate in our case, as serotyping is not routinely performed in Switzerland. However, the advanced clinical findings leading to entropion necessitating surgery emphasise not only the need for early diagnosis and treatment of this disease but also the need for thorough clinical examination including eversion of the upper lid and inspection of the tarsal conjunctiva in any patient with conjunctivitis. '' Further on in the same paragraph, we state, ''It is not clear why the EDCCS and BDES obtained the strong effects they did".
In both cases these results were incorrectly attributed to the BDES. These two sentences should have instead cited Reference 79, which pertains to data from the NHANES III study. Citations to References 49 (BDES) and 79 (NHANES II) are correct in the 3 tables.
